A pharmacogenomics test can help.
A pharmacogenomics test uses information about a person’s genetic makeup to help clinicians choose medications and doses that are likely to work best.
Depending on your genetic makeup, some drugs may work more or less effectively for you than they do in other people. Likewise, some drugs may produce more or fewer side effects in you than in someone else.
Information about your genetic makeup can assist your doctor in prescribing medicines that are most likely to work for you, and avoid dosages and prescribing combinations that may cause you to experience adverse drug reactions.
How does the test work?
If you choose to be tested, a cheek swab or a blood sample is collected and sent to our DNA lab for testing. We will determine your body’s response to medications, with results sent to your physician within 1 to 2 weeks.
What do the results tell you?
Results from your Pharmacogenomics DNA test will provide information on how quickly your body metabolizes or filters a given drug:
Rapid metabolizers flush certain drugs quickly from their system and may not realize any benefit from taking a normal or standard dose.
Slow metabolizers build up normal doses of certain medication to potentially dangerous levels.
Normal metabolizers can accept a normal and standard dose without worrying about adverse drug reactions based on genetics.
Comprehensive Pharmacogenomics Gene Test includes the following genes:
APOE, COMT, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, F2, F5, MTHFR, SLCO1B1, TPMT, VKORC1
Pharmacogenomics is the study of how human genetic variation affects an individual’s response to drug therapies. Understanding a patient’s genetic background allows a physician to predict how a prescribed drug will relate with that patient, giving the clinician insight into not only clinical efficacy, but also potential undesired drug reactions.
- Biologic enzymes found in our liver act upon certain target substrates and then trigger a metabolic chain reaction.
- This data can then be used to help physicians avoid drugs that would be inefficiently metabolized and guide them towards drugs that use more robust metabolic pathways.
FDA studies estimate that 7% of hospitalized patients have a serious adverse drug reaction with a fatality rate of 0.32%.
By isolating and examining the regions of a patient’s DNA that code for the enzymes of interest, we can provide the following answers:
Patients have differences in DNA that impact drug metabolism which may increase their likelihood of an adverse drug reaction:
Who To Test?
Personalized Genomics advises pharmacogenomics testing for patients that meet one or more of the following conditions: